Strategic collaboration for Bexobrutideg commercialization signals major catalyst for BTK-mediated diseases.
What changed
NURIX THERAPEUTICS, INC. (NRIX) DISCUSSES STRATEGIC COLLABORATION FOR DEVELOPMENT AND COMMERCIALIZATION OF BEXOBRUTIDEG FOR BTK-MEDIATED DISEASES - SLIDESHOW — VIA SEEKINGALPHA